Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus Vaccine

 Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus Vaccine

Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus Vaccine

Shots:

  • Sanofi will leverage its previous development work for a SARS vaccine and utilize its recombinant DNA platform to accelerate the development of a vaccine candidate against coronavirus
  • The SARS vaccine candidates that were developed by Protein Sciences (acquired by Sanofi in 2017) provides a head start in expediting a COVID-19 vaccine
  • Additionally, in Dec’2019, Sanofi collaborates with BARDA to form state of the art facilities in the US for the sustainable production of an adjuvanted recombinant vaccine to be used in influenza pandemic and is based on the same platform that will be used for the COVID-19 program

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Livemint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post